RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review
Abstract
:1. Introduction
2. The RANK/RANKL Signaling Network
3. Functional Role of RANK/RANKL Signaling
4. RANK-Mediated Signaling and Cervical Cancer
5. The Effect of RANK Signaling Inhibition on Non-Bone Tumor Growth in Humans
6. A Window of Opportunity Neoadjuvant Phase II Study Assessing the Therapeutic Potential of RANK/RANKL Signaling Inhibition in Patients with Primary and Recurrent Squamous Carcinoma of the Uterine Cervix (ISS 20177041)
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics 2012. CA Cancer J. Clin. 2015, 65, 87–108. [Google Scholar] [CrossRef] [PubMed]
- Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342–350. [Google Scholar] [CrossRef] [PubMed]
- Marth, C.; Landoni, F.; Mahner, S.; McCormack, M.; Gonzalez-Martin, A.; Colombo, N. Cervical cancer: ESMO clinical practice guidelines. Ann. Oncol. 2017, 28, 72–83. [Google Scholar] [CrossRef]
- van Dam, P.A.; Rolfo, C.; Ruiz, R.; Pauwels, P.; Van Berckelaer, C.; Trinh, X.B.; Ferri Gandia, J.; Bogers, J.P.; Van Laere, S. Potential new biomarkers for squamous carcinoma of the uterine cervix. ESMO Open 2018, 3, e000352. [Google Scholar] [CrossRef] [PubMed]
- van Dam, P.A.; Rolfo, C.; Ruiz, R. Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix. Eur. J. Surg. Oncol. 2017, 43, 2245–2247. [Google Scholar] [CrossRef]
- Bonte, A.S.; Luyckx, A.; Wyckmans, L.; Trinh, X.B.; van Dam, P.A. Quality indicators for the management of endometrial, cervical and ovarian cancer. Eur. J. Surg. Oncol. 2019, 45, 528–537. [Google Scholar] [CrossRef] [PubMed]
- Tewari, K.S.; Sill, M.W.; Penson, R.T.; Huang, H.; Ramondetta, L.M.; Landrum, L.M.; Oaknin, A.; Reid, T.J.; Leitao, M.M.; Michael, H.E.; et al. Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017, 390, 1654–1663. [Google Scholar] [CrossRef]
- van Dam, P.A.; van Dam, P.H.; Rolfo, C.; Giallombardo, M.; Van Berckelaer, C.; Trinh, X.B.; Altintas, S.; Huizing, M.; Papadimitriou, K.; Tjalma, W.A.; et al. In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment. Oncotarget 2016, 7, 2780–2795. [Google Scholar] [CrossRef]
- Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 2017, 543, 378–384. [Google Scholar] [CrossRef]
- De Felice, F.; Marchetti, C.; Palaia, I.; Ostuni, R.; Muzii, L.; Tombolini, V.; Benedetti Panici, P. Immune check-point in cervical cancer. Crit. Rev. Oncol. Hematol. 2018, 129, 40–43. [Google Scholar] [CrossRef] [PubMed]
- Ahern, E.; Smyth, M.J.; Dougall, W.C.; Teng, M.W.L. Roles of the RANKL-RANK axis in antitumour immunity—Implications for therapy. Nat. Rev. Clin. Oncol. 2018, 19. [Google Scholar] [CrossRef] [PubMed]
- Lee, W.H.; Seo, D.; Lim, S.G.; Suk, K. Reverse signaling of tumor necrosis factor superfamily proteins in macrophages and microglia: Superfamily portrait in the neuroimmune interface. Front. Immunol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Ward-Kavanagh, L.K.; Lin, W.W.; Šedý, J.R.; Ware, C.F. The TNF Receptor Superfamily in Co-stimulating and Cco-inhibitory responses. Immunity 2016, 44, 1005–1019. [Google Scholar] [CrossRef]
- Walsh, M.C.; Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone and beyond. Front. Immunol. 2014. [Google Scholar] [CrossRef]
- Wong, B.R.; Josien, R.; Lee, S.Y.; Sauter, B.; Li, H.L.; Steinman, R.M.; Choi, Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 1997, 186, 2075–2080. [Google Scholar] [CrossRef] [PubMed]
- Sigl, V.; Jones, L.P.; Penninger, J.M. RANKL/RANK: From bone loss to the prevention of breast cancer. Open Biol. 2016, 6, 160230. [Google Scholar] [CrossRef] [PubMed]
- van Dam, P.; Verhoeven, Y.; Trinh, X.B.; Wouters, A.; Lardon, F.; Prenen, H.; Smits, E.; Baldewijns, M.; Lammens, M. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit. Rev. Oncol. Hematol. 2019, 133, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Ikeda, T.; Kasai, M.; Utsuyama, M.; Harikowa, K. Determination of three isoforms of the receptor activator of nuclear factor-kappa B ligand and their differential expression in bone and thymus. Endocrinology 2001, 142, 1419–1426. [Google Scholar] [CrossRef]
- Gonzalez-Suarez, E.; Sanz-Moreno, A. RANK as a therapeutic target in cancer. FEBS J. 2016, 283, 2018–2033. [Google Scholar] [CrossRef]
- Schneeweis, L.A.; Willard, D.; Milla, M.E. Functional dissection of osteoprotegerin and its interactions with receptor activator of NF-kappaB ligand. J. Biol. Chem. 2005, 280, 41155–41164. [Google Scholar] [CrossRef]
- Millian, M.M. The role of estrogen receptor in bone cells. Clin. Rev. Bone Miner. Metab. 2015, 13, 105–112. [Google Scholar] [CrossRef]
- Theolaire, S.; Wittrant, Y.; Kwantat, S.; Fortun, Y.; Redeni, F.; Heymann, D. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiologic bone remodeling. Cytokine Growth Factor Rev. 2004, 15, 457–475. [Google Scholar] [CrossRef]
- Renema, N.; Navet, B.; Heymann, M.F.; Lezot, F.; Heymann, D. RANK-RANKL signaling in cancer. Biosci. Rep. 2016, 36, e00366. [Google Scholar] [CrossRef]
- Luo, J.; Yang, Z.; Ma, Y.; Yue, Z.; Lin, H.; Qu, G.; Huang, J.; Dai, W.; Li, C.; Zheng, C.; et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 2016, 22, 539–546. [Google Scholar] [CrossRef] [PubMed]
- Papanastasiou, A.D.; Sirinian, C.; Plakoula, E.; Zolota, V.; Zarkadis, I.K.; Kalofonos, H.P. RANK and EGFR in invasive breast carcinoma. Breast Cancer Res. 2017, 216–217, 61–66. [Google Scholar] [CrossRef]
- Papanastasiou, A.D.; Sirinian, C.; Kalofonos, H.P. Identification of novel human receptor activator of NF-kB isoforms generated through alternative spicing: Implications in breast cancer cell survival and migration. Breast Cancer Res. 2012, 1, R112. [Google Scholar] [CrossRef]
- Boyce, B.F.; Xing, L. The RANKL/RANK/OPG pathway. Curr. Osteoporos. Rep. 2007, 5, 98–104. [Google Scholar] [CrossRef]
- Li, H.; Hong, S.; Qian, J.; Zheng, Y.; Yang, J.; Yi, Q. Cross talk between the bone and immune systems: Osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood 2009, 116, 210–217. [Google Scholar] [CrossRef] [PubMed]
- Teitelbaum, S.L. Bone resorption by osteoclasts. Science 2000, 289, 1504–1508. [Google Scholar] [CrossRef]
- Gonzalez-Suarez, E.; Jacob, A.P.; Jones, J.; Miller, R.; Roudier-Meyer, M.P.; Erwert, R.; Pinkas, J.; Branstetter, D.; Dougall, W.C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468, 103–107. [Google Scholar] [CrossRef]
- Akiyama, T.; Shinzawa, M.; Akiyama, N. RANKL-RANK interaction in immune regulatory systems. World J. Orthop. 2012, 18, 142–150. [Google Scholar] [CrossRef]
- Sobacchi, C.; Frattini, A.; Guerrini, M.M.; Abinun, M.; Pangrazio, A.; Susani, L.; Bredius, R.; Mancini, G.; Cant, A.; Bishop, N.; Grabowski, P.; et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 2007, 39, 960–962. [Google Scholar] [CrossRef] [PubMed]
- Leibbrandt, A.; Penninger, J.M. Novel functions of RANK(L) signaling in the immune system. Adv. Exp. Med. Biol. 2010, 658, 77–94. [Google Scholar]
- de Groot, A.F.; Appelman-Dijkstra, N.M.; van der Burg, S.H.; Kroep, J.R. The anti-tumor effect of RANKL inhibition in malignant solid tumors—A systematic review. Cancer Treat. Rev. 2018, 62, 18–28. [Google Scholar] [CrossRef]
- Bishop, G.A.; Moore, C.R.; Xie, P.; Stunz, L.L.; Kraus, Z.J. TRAF proteins in CD40 signaling. Adv. Exp. Med. Biol. 2007, 597, 131–151. [Google Scholar]
- Tilborghs, S.; Corthouts, J.; Verhoeven, Y.; Arias, D.; Rolfo, C.; Trinh, X.B.; van Dam, P.A. The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit. Rev. Oncol. Hematol. 2017, 120, 141–150. [Google Scholar] [CrossRef]
- Josien, R.; Wong, B.R.; Li, H.L.; Steinman, R.M.; Choi, Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 1999, 162, 2562–2568. [Google Scholar] [PubMed]
- Josefowicz, S.Z.; Lu, L.F.; Rudensky, A.Y. Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 2012, 30, 531–564. [Google Scholar] [CrossRef]
- Hon, H.; Rucker, E.B.; Hennighausen, L.; Jacob, J. Bcl-xL is critical for dendritic cell survival in vivo. J. Immunol. 2004, 173, 4425–4432. [Google Scholar] [CrossRef]
- Prenen, H.; Mazzone, M. Tumor-associated macrophages: A short compendium. Cell. Mol. Life Sci. 2019. [Google Scholar] [CrossRef] [PubMed]
- Baay, M.; Brouwer, A.; Pauwels, P.; Peeters, M.; Lardon, F. Tumor cells and tumor-associated macrophages: Secreted proteins as potential targets for therapy. Clin. Dev. Immunol. 2011, 565187. [Google Scholar] [CrossRef]
- Fujimura, T.; Ring, S.; Umansky, V.; Mahnke, K.; Enk, A.H. Regulatory T cells (Treg) stimulate B7-H1 expression in myeloid derived suppressor cells (MDSC) in ret melanomas. J. Investig. Dermatol. 2012, 132, 1239–1246. [Google Scholar] [CrossRef] [PubMed]
- Noy, R.; Pollard, J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014, 41, 49–61. [Google Scholar] [CrossRef]
- Liu, W.; Xu, C.; Zhao, H.; Xia, P.; Song, R.; Gu, J.; Liu, X.; Bian, J.; Yuan, Y.; Liu, Z. Osteoprotegrin induces apoptosis of osteoclasts and osteoclast precursor cells via Fas/Fas ligand pathway. PLoS ONE 2015, 16, 1–14. [Google Scholar] [CrossRef]
- Dougall, W.C. Molecular pathways: Osteoclast dependent and osteoclast independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin. Cancer Res. 2012, 18, 326–335. [Google Scholar] [CrossRef]
- Schmiedel, B.J.; Grosse-Hovest, L.; Salih, H.R. A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL? Oncoimmunology 2013, 2, e23850. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Christoph, F.; König, F.; Lebentrau, S.; Jandrig, B.; Krause, H.; Strenziok, R.; Schostak, M. RANKL/RANK/OPG cytokine receptor system: MRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J. Urol. 2018, 36, 187–192. [Google Scholar] [CrossRef] [PubMed]
- Chu, C.Y.; Chung, L.W. RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev. 2014, 33, 497–509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cross, S.S.; Harrison, R.F.; Balasubramanian, S.P.; Lippitt, J.M.; Evans, C.A.; Reed, M.W.; Holen, I. Expression of receptor activator nuclear factor kappa beta lingand (RANKL) and tumour necrosis factor related apoptosis inducing ligand (TRAIL) in breast cancer, and its relations with osteoprotegrin, estrogen receptor and clinicopathological variables. J. Clin. Pathol. 2006, 59, 716–720. [Google Scholar] [CrossRef]
- Reid, P.E.; Brown, N.J.; Holen, I. Breast cancer cells stimulate osteoprotegerin production by endothelial cells through direct cell contact. Mol. Cancer 2009, 8, 49. [Google Scholar] [CrossRef]
- Santini, D.; Schiavon, G.; Vincenzi, B.; Gaeta, L.; Pantano, F.; Russo, A.; Ortega, C.; Porta, C.; Galluzzo, S.; Armento, G.; et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE 2011, 6, e19234. [Google Scholar] [CrossRef] [PubMed]
- Cui, X.; Peng, H.; Jin, J.; Li, T.; Zhang, S.; Jin, T.; Li, S.; Liu, C.; Liang, W.; Li, F.; et al. RANK overexpression as a novel esophageal cancer marker: Validated immunohistochemical analysis of two different ethnicities. Int. J. Clin. Exp. Pathol. 2015, 8, 2249–2258. [Google Scholar]
- De Castro, J.; Garcia, R.; Garrido, P.; Isla, D.; Massuti, B.; Blanca, B.; Vazquez, J. Therapeutic potential of denosumab in patients with lung cancer: Beyond prevention of skeletal complications. Clin. Lung Cancer 2015, 16, 431–446. [Google Scholar] [CrossRef]
- Heymann, M.F.; Riet, A.; Le Goff, B.; Battaglia, S.; Paineau, J.; Heymann, D. OPG, RANK and RANK ligand expression in thyroid lesions. Regul. Pep. 2008, 148, 46–53. [Google Scholar]
- Ito, R.; Nakayama, H.; Yoshida, K.; Kuraoka, K.; Motoshita, J.; Oda, N.; Oue, N.; Yasui, W. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003, 443, 146–151. [Google Scholar] [CrossRef]
- Mizutani, Y.; Matsubara, H.; Yamamoto, K.; Nan Li, Y.; Mikami, K.; Okihara, K.; Kawauchi, A.; Bonavida, B.; Miki, T. Prognostic significance of serum osteoprotegrin levels in patients with bladder carcinoma. Cancer 2004, 101, 1794–1802. [Google Scholar] [CrossRef] [PubMed]
- Naumnik, W.; Płońska, I.; Ossolińska, M.; Nikliński, J.; Naumnik, B. Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer. Adv. Exp. Med. Biol. 2018, 1047, 1–6. [Google Scholar] [CrossRef]
- Sarink, D.; Schock, H.; Johnson, T.; Overvad, K.; Holm, M.; Tjønneland, A.; Boutron-Ruault, M.C.; His, M.; Kvaskoff, M.; Boeing, H.; et al. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prev. Rev. 2017, 10, 525–534. [Google Scholar] [CrossRef]
- Palafox, M.; Ferrer, I.; Pellegrini, P.; Vila, S.; Hernadez-Ortega, S.; Urricoechea, A.; Climent, F.; Soler, M.T.; Munoz, P.; Vinals, F.; et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 2012, 72, 2678–2688. [Google Scholar] [CrossRef] [PubMed]
- Faget, J.; Contat, C.; Zangger, N.; Peters, S.; Meylan, E. RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma. J. Thorac. Oncol. 2018, 13, 387–398. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Wang, J.; Ni, T.; Wang, L.; Wang, Y.; Sun, X. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget 2016, 18, 25328–25339. [Google Scholar] [CrossRef]
- Pellegrini, P.; Cordero, A.; Gallego, M.I.; Dougall, W.C.; Munoz, P.; Pujana, M.A.; Gonzalez-Suarez, E. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells 2013, 31, 1954–1965. [Google Scholar] [CrossRef] [Green Version]
- Yamada, T.; Tsuda, M.; Takahashi, T.; Totsuka, Y.; Shindoh, M.; Ohba, Y. RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression. Am. J. Pathol. 2011, 178, 2845–2856. [Google Scholar] [CrossRef] [PubMed]
- Min, J.K.; Kim, Y.M.; Kim, Y.M.; Kim, E.C.; Gho, Y.S.; Kang, I.J.; LEE, S.Y.; Kong, Y.Y.; Kwon, Y.G. Vascular endothelial growth factor upregulates expression of receptor activator of NF-kB (RANK) in endothelial cells: Concomitant increase of angiogenic responses to RANK ligand. J. Biol. Chem. 2003, 278, 39548–39557. [Google Scholar] [CrossRef] [PubMed]
- Shang, W.Q.; Li, H.; Liu, L.B.; Chang, K.K.; Yu, J.J.; Xie, F.; Li, M.Q.; Yu, J.J. RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion. Oncol. Rep. 2015, 34, 3007–3016. [Google Scholar] [CrossRef]
- Demoulin, S.A.; Somja, J.; Duray, A.; Roncarati, P.; Delvenne, P.O.; Herfs, M.F.; Hubert, P.M. Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANK secretion. Oncoimmunology 2015, 4, e10008334-1. [Google Scholar] [CrossRef]
- Ma, D.; Chang, L.Y.; Zhao, S.; Zhao, J.J.; Xiong, Y.J.; Cao, F.Y.; Yuan, L.; Zhang, Q.; Wang, X.Y.; Geng, M.L.; et al. KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression. Sci. Rep. 2017, 7, 15683. [Google Scholar] [CrossRef] [Green Version]
- Tang, Z.N.; Zhang, F.; Tang, P.; Qi, X.W.; Jiang, J. Hypoxia induces RANK and RANKL expression by activating HIF-1 alpha in breast cancer cells. Biochem. Biophys. Res. Commun. 2011, 408, 411–416. [Google Scholar] [CrossRef]
- Jia, L.; Li, F.; Shao, M.; Zhang, W.; Zhang, C.; Zhao, X.; Luan, H.; Qi, Y.; Zhang, P.; Liang, L.; et al. IL-8 is upregulated in cervical cancer tissues and is associated with the proliferation and migration of HeLa cervical cancer cells. Oncol. Lett. 2018, 15, 1350–1356. [Google Scholar] [CrossRef] [PubMed]
- Fujimoto, J.; Sakaguchi, H.; Aoki, I.; Tamaya, T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 2000, 60, 2632–2635. [Google Scholar] [PubMed]
- Wu, S.; Shang, H.; Cui, L.; Zhang, Z.; Zhang, Y.; Li, Y.; Wu, J.; Li, R.K.; Xie, J. Targeted blockade of interleukin-8 abrogates its promotion of cervical cancer growth and metastasis. Mol. Cell. Biochem. 2013, 375, 69–79. [Google Scholar] [CrossRef]
- García Paz, F.; Madrid Marina, V.; Morales Ortega, A.; Santander González, A.; Peralta Zaragoza, O.; Burguete García, A.; Torres Poveda, K.; Moreno, J.; Alcocer González, J.; Hernandez Marquez, E.; et al. The relationship between the antitumor effect of the IL-12 gene therapy and the expression of Th1 cytokines in an HPV16-positive murine tumor model. Med. Inflamm. 2014, 2014, 510846. [Google Scholar] [CrossRef]
- Xing, L.; Men, X.; Han, L.; Li, M.; Wang, Y. Tumor OPG expression is associated with prognosis of cervical cancer in Chinese patients underwent surgical treatment. Int. J. Clin. Exp. Med. 2016, 9, 3675–3680. [Google Scholar]
- Mysona, D.; Pyrzak, A.; Allen, J.; Bai, S.; Sharma, A.; She, J.X.; Rungruang, B.J.; Ghamande, B.J. MMP7: A potential biomarker of invasive cervix cancer: A prospective pilot study. JCO 2016, 34, 15. [Google Scholar] [CrossRef]
- Dawson, S.; Pickworth, J.; Rothman, A.M.; Iremonger, J.; Arnold, N.; Francis, S.; Lawrie, A. OPG regulates pulmonary smooth muscle cell proliferation and the expression of Pah-associated genes via Fas. Thorax 2014, 69, A5. [Google Scholar] [CrossRef]
- Kobayashi, A.; Donaldson, D.S.; Kanaya, T.; Fukuda, S.; Baillie, J.K.; Freeman, T.C.; Ohno, H.; Williams, I.R.; Mabbott, N.A. Identification of novel genes selectively expressed in the follicle epithelium from the meta-analysis of transcriptomics data from multiple mouse cell and tissue populations. DNA Res. 2012, 19, 407–422. [Google Scholar] [CrossRef]
- Sasaki, Y.; Koyama, R.; Maruyama, R.; Hirano, T.; Tamura, M.; Sugisaka, J.; Suzuki, H.; Igogawa, M.; Shinomura, Y.; Tokino, T. CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Cancer Biol. Ther. 2012, 13, 1512–1521. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peters, S.; Clézardin, P.; Marquez-Rodas, I.; Niepel, D.; Gedye, C. The RANK/RANKL axis: An opportunity for drug repurposing in cancer. Clin. Transl. Oncol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.; et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017, 9, 34. [Google Scholar] [CrossRef] [Green Version]
- Hanley, D.A.; Adachi, J.D.; Bell, A.; Brown, V. Denosumab: Mechanism of action and clinical outcomes. Int. J. Clin. Pract. 2012, 66, 1139–1146. [Google Scholar] [CrossRef] [PubMed]
- Castellano, D.; Sepulveda, J.M.; Garcia-Escobar, I.; Rodriguez-Antolin, A.; Sundlov, A.; Cortes-Funes, H. The role of RANK-ligand inhibition in cancer: The story of denosumab. Oncologist 2011, 16, 136–145. [Google Scholar] [CrossRef]
- Scagliotti, G.V.; Hirsh, V.; Siena, S.; Henry, D.H.; Woll, P.J.; Manegold, C.; Solal-Celigny, P.; Rodriguez, G.; Krzakowski, M.; Mehta, N.D.; et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J. Thorac. Oncol. 2012, 7, 1823–1829. [Google Scholar] [CrossRef]
- Peters, S.; Danson, S.J.; hasan, B.; Reinmuth, N.; Majem, M.; Tournoy, K.G. A randomized phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial (abstract 1385). Ann. Oncol. 2018, 29, 008. [Google Scholar] [CrossRef]
- Gnant, M.; Pfeiler, G.; Steger, G.; Egle, D.; Greil, R.; Fitzal, F.; Wette, V.; Haslbauer, F.; Melbiner, E.; Melbinger-Zeinitzer, E.; et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3425 postmenopausal patients in the ABCSG-18 trial. J. Clin. Oncol. 2018, 36, S500. [Google Scholar] [CrossRef]
- Coleman, R.E.; Finkelstein, D.; Martin, M.; Iwata, H.; Glaspy, J.A.; Zhou, Y.; Jandial, D.; Chan, A. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled study. J. Clin. Oncol. 2018, 36, S501. [Google Scholar] [CrossRef]
- Coleman, R.E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston, S.J.; Grieve, R.J.; Barrett-Lee, P.J.; et al. AZURE investigators. Breast cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 2011, 365, 1396–1405. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, B.; Maetens, M.; Salgado, R.; venet, D.; Vuylsteke, P.; Polastro, L.; Wildiers, H.; Simon, P.; Lindeman, G.; Larsimont, D.; et al. D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK ligand inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer. Cancer Res. 2018, 78, CT101. [Google Scholar] [CrossRef]
- Ahern, E.; Harjunpää, H.; Barkauskas, D.; Allen, S.; Takeda, K.; Yagita, H.; Wyld, D.; Dougall, W.C.; Teng, M.W.L.; Smyth, M.J. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clin. Cancer Res. 2017, 23, 5789–5801. [Google Scholar] [CrossRef]
- Afzal, M.Z.; Shirai, K. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: A retrospective analysis at a tertiary care center. Melanoma Res. 2018, 28, 341–347. [Google Scholar] [CrossRef]
- Smyth, M.J.; Yagita, H.; McArthur, G.A. Combination of anti-CTL-4 and anti-RANKL in metastatic melanoma. J. Clin. Oncol. 2016, 34, e104–e106. [Google Scholar] [CrossRef]
- Nolan, E.; Vaillant, F.; Branstetter, D.; Pal, B.; Giner, D.; Whitehead, L.; LOK, S.W.; Mann, G.B.; Rohrbach, K.; Huang, L.Y.; et al. RANK ligand as a potential target for breast cancer prevention in BRCA1 mutation carriers. Nat. Med. 2016, 22, 933–939. [Google Scholar] [CrossRef] [PubMed]
- Ahern, E.; Harjunpaa, H.; O’Donnell, J.S.; Allen, S.; Dougall, W.C.; Teng, M.W.; Smyth, M.J. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PDlL1 and CTL4 A blockade in mouse models of cancer. OncoImmunology 2018, 6, e1431088. [Google Scholar] [CrossRef] [PubMed]
- Bakhru, P.; Zhu, M.L.; Wang, H.H.; Hong, L.K.; Khan, I.; Mouchess, M.; Gulati, A.S.; Starmer, J.; Hou, Y.; Sailer, D.; et al. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2017, 2, e93265. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
van Dam, P.A.; Verhoeven, Y.; Jacobs, J.; Wouters, A.; Tjalma, W.; Lardon, F.; Van den Wyngaert, T.; Dewulf, J.; Smits, E.; Colpaert, C.; et al. RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. Int. J. Mol. Sci. 2019, 20, 2183. https://doi.org/10.3390/ijms20092183
van Dam PA, Verhoeven Y, Jacobs J, Wouters A, Tjalma W, Lardon F, Van den Wyngaert T, Dewulf J, Smits E, Colpaert C, et al. RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. International Journal of Molecular Sciences. 2019; 20(9):2183. https://doi.org/10.3390/ijms20092183
Chicago/Turabian Stylevan Dam, Peter A., Yannick Verhoeven, Julie Jacobs, An Wouters, Wiebren Tjalma, Filip Lardon, Tim Van den Wyngaert, Jonatan Dewulf, Evelien Smits, Cécile Colpaert, and et al. 2019. "RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review" International Journal of Molecular Sciences 20, no. 9: 2183. https://doi.org/10.3390/ijms20092183